5 Best Covid Vaccine and Pill Stocks To Invest In

In this article, we discuss the 5 best Covid vaccine and pill stocks to invest in. If you want to read our detailed analysis of these stocks, go directly to the 11 Best Covid Vaccine and Pill Stocks To Invest In.

5. Gilead Sciences, Inc. (NASDAQ:GILD)

Number of Hedge Fund Holders: 54

Gilead Sciences, Inc. (NASDAQ:GILD) recently posted earnings for the third quarter, reporting earnings per share of $2.65, beating estimates by $0.87. The revenue over the period was $7.4 billion, up 13% year-on-year and beating predictions by $1 billion. A few weeks before the results, the company had obtained regulatory approval of a new drug for the treatment of HIV patients. The firm has also inked an agreement with drug giant Merck for collaboration on a breast cancer treatment. 

On October 19, investment advisory Cowen initiated coverage of Gilead Sciences, Inc. (NASDAQ:GILD) stock with an Outperform rating. BMO Capital also has a positive outlook on the company. 

At the end of the second quarter of 2021, 54 hedge funds in the database of Insider Monkey held stakes worth $1.7 billion in Gilead Sciences, Inc. (NASDAQ:GILD), down from 65 in the previous quarter worth $2.6 billion.

In its Q3 2020 investor letter, Nelson Roberts Investment Advisors, an asset management firm, highlighted a few stocks and Gilead Sciences, Inc. (NASDAQ:GILD) was one of them. Here is what the fund said:

“In the healthcare sector, we sold our position in Gilead (NASDAQ: GILD) as there are no near or medium-term growth drivers for the company. Its popular HIV drug, Truvada, is going off patent this year. Additionally, UnitedHealth Group said it would not cover Gilead’s other HIV drug, Descovy. Lastly, the multiple acquisitions that Gilead has made recently are not ready for prime time, and it will likely be two years or more before any of Gilead’s new drugs have a meaningful impact on revenue.”